What are the side effects of Reboxetine?

Users most often report high body, sweating, drowsiness, cough, worse cognition. Side effects came up 5 times across 10 reports.

User reports can't establish safety. PubMed lists 55 meta-analyses and 142 randomized trials. Talk to a doctor or pharmacist, especially if you take other medication.

Reboxetine side effects

Across 10 first-hand reports, people mentioned a side effect 5 times (about 50 per 100 reports). The most common: high body, sweating, drowsiness. User reports show what people notice — they can't tell you whether Reboxetine is safe for you.

Reported side effects

high body1

sweating1

drowsiness1

cough1

worse cognition1

In their own words

“Then subsequent doses make me feel like I'm dying with super high body temperature, sweating, drowsiness, cough, and way worse cognition than baseline.”

MixedRead the discussion ↗

Is Reboxetine safe? What the research covers

AResearch: Strong55 meta-analyses · 142 randomized trials on PubMed

Mol Psychiatry · 2023

Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis

Conclusion: Compared to placebo, venlafaxine was associated with a lower incidence of dizziness, while desvenlafaxine, sertraline, and vortioxetine were associated with a higher incidence of nausea/vomiting. In conclusion, desvenlafaxine, paroxetine, venlafaxine, and vortioxetine had reasonable efficacy, acceptability, and tolerability in the treatment of adults with stable MDD.

Cochrane Database Syst Rev · 2023

Pharmacological treatments in panic disorder in adults: a network meta-analysis

Conclusion: In terms of efficacy, SSRIs, SNRIs (venlafaxine), TCAs, MAOIs and BDZs may be effective, with little difference between classes. However, it is important to note that the reliability of these findings may be limited due to the overall low quality of the studies, with all having unclear or high risk of bias across multiple domains. Within classes, some differences emerged. For example, amongst the SSRIs paroxetine and fluoxetine seem to have stronger evidence of efficacy than sertraline. Benzodiazepines appear to have a small but significant advantage in terms of tolerability (incidence of drop